NCT07179341Completed
Survival Nomogram for Patients With Thymic Carcinoma
Source: ClinicalTrials.gov · Last updated 17 Sept 2025
Brief summary (registry, in English)
Background Thymic carcinoma (TC) is a rare and aggressive mediastinal malignancy with poor prognosis. Our study aimed to develop a nomogram to predict overall survival (OS) of TC patients. Method A total of 156 patients confirmed TC between 1996 and 2023 were selected from our database. They were divided into training cohort, validation cohort one and validation cohort two. A nomogram was constructed based on the risk factors affecting prognosis using a Cox proportional hazards regression model. The discrimination and calibration of the nomogram were evaluated by C-index, AUC and curve of calibration. The three cohorts were divided into low-risk and high-risk subgroups.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 156 (actual)
- First submitted
- 4 Sept 2025
- Start date
- 9 Jul 2024
- Primary completion date
- 1 Jul 2025
- Lead sponsor
- Weijie Ye
- Diseases
- Childhood cancers
- NCT number
- NCT07179341
What you commit to
- Study type: Interventional
- Participants enrolled: 156
- From 9 Jul 2024 to the primary completion date, 1 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The patient did not obtain a complete pathological report after surgery.
Other
- The patient had two types of primary tumors concurrently including TC.
- The tumor in the thymus was not primary but metastatic, having originated from a different primary site.
Who the study is looking for
- The diagnosis of TC in patients should be confirmed through endoscopic tumor biopsy or surgery to obtain tumor tissue for pathological confirmation under light microscope, and even further confirmed through immunohistochemical staining.
- Patients should accept surgery and obtain complete postoperative pathological reports in order to assess Masaoka-Koga staging.
- Patients who accepted surgery should be followed up at least six months or reached the endpoint event.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| 651 Dongfeng Road East, Yuexiu District, Guangzhou, P.R. China Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.